Biofrontera Inc (BFRI) — Titan Protect Analysis

BFRI

Biofrontera Inc

Healthcare · ·

$0.94

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$13M

Total market value of the company

Trailing P/E

N/A

Forward P/E

3.16

Based on estimated future earnings — lower means cheaper

Rev Growth

+17.4%

Year-over-year revenue change

Profit Margin

-25.7%

How much profit the company keeps from each dollar of revenue

ROE

-339.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.88

+528% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 2 analysts covering this stock

About Biofrontera Inc

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

https://www.biofrontera-us.com

Country: United States Employees: 84 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.443

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0208

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.008

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-0.5%

Historical annualised return based on price data

Max Drawdown

-59.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.91

Less volatile than the market — more defensive

52W High

$1.19

21% below the year high

52W Low

$0.56

68% above the year low

Avg Volume

174,228

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.98

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

127.25

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

77.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-39.0%

Profit from core operations before interest and tax

Free Cash Flow

$1M

Positive — the business generates more cash than it spends

Revenue (TTM)

$43M

Total revenue over the last 12 months

Net Income

$-11,085,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$9.00

Target Median

$5.88

Target Low

$2.75

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go